AVI BioPharma to Present at the JMP and Maxim Healthcare Conferences
October 01 2008 - 12:00PM
Marketwired
AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs,
today announced that Dr. Leslie Hudson, AVI's President and CEO,
will present at two upcoming healthcare conferences.
The first is the JMP Securities Healthcare Focus Conference, to
be held October 6-7, 2008 at Le Parker Meridien Hotel in New York
City. Dr. Hudson's presentation is scheduled on October 6 at 4:30
p.m. Eastern time. Slides and the webcast link will be available on
the Company's website at www.avibio.com after the presentation.
On October 7, Dr. Hudson will present at the Maxim Group Growth
Conference, held at the Grand Hyatt Hotel in New York. His
presentation is scheduled for 2:00 p.m. Eastern time. While
currently scheduled, presentation times in both conferences are
subject to change.
At both conferences, Dr. Hudson will provide an update on the
continuing transition of AVI from an antisense pioneer into a
leading discoverer and developer of RNA-based drugs. The corporate
overview will include an update on AVI's Duchenne muscular
dystrophy program (DMD), its biodefense projects (which include
significant data from the Company's ongoing Ebola and Marburg virus
programs in collaboration with the Department of Defense), its
partnership with Cook Medical in the development of a new,
innovative drug eluting stent for the prevention of cardiovascular
restenosis, and the Company's renewed focus on developing
partnerships and collaborations to forward other promising programs
based on AVI's proprietary compounds and their novel RNA-based
applications.
About AVI BioPharma
AVI BioPharma is focused on the discovery and development of
RNA-based drugs using the company's expanded portfolio of
proprietary antisense compounds (PMOs). The company's technology
applications leverage distinct mechanisms of action in a range of
genetic diseases, genetic disorders and the genetic code of
disease-causing organisms. The emerging field of directed
alternative RNA splicing represents AVI's newest and most exciting
application based on the company's core antisense technology.
Functional attributes of this approach may include correcting
genetic defects (RNA mutations; which AVI believes could produce
promising treatments for Duchenne muscular dystrophy), coding for
novel soluble receptors (an exciting and novel approach which could
have application in the treatment of inflammatory diseases such as
rheumatoid arthritis), and the reduction in activity of immune
modulators in disease states (currently being applied to IL-10).
AVI's RNA-based drug programs also include blocking mRNA
translation. In AVI's biodefense program, this application has been
successful against the single-stranded RNA viruses Ebola Zaire and
Marburg Musoke in non-human primates and may have value against
other viral targets such as HCV, Dengue, Junin, influenza and RSV
viruses. This application also will be evaluated in the clinic for
the treatment of cardiovascular restenosis by our partner Cook
Medical. More information about AVI is available at
www.avibio.com.
"Safe Harbor" Statement under the Private Securities Litigation
Reform Act of 1995: The statements that are not historical facts
contained in this release are forward-looking statements that
involve risks and uncertainties, including, but not limited to, the
results of research and development efforts, the results of
preclinical and clinical testing, the effect of regulation by the
FDA and other agencies, the impact of competitive products, product
development, commercialization and technological difficulties, and
other risks detailed in the company's Securities and Exchange
Commission filings.
AVI Press and Investor Contact: Michael Hubbard Email Contact
Director of Corporate Communications (503) 227-0554
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jun 2024 to Jul 2024
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jul 2023 to Jul 2024